Cross-Reactive Immunity Induced by H5N1 Vaccine
Author Information
Author(s): Isabel Leroux-Roels, Roger Bernhard, Pascal Gérard, Mamadou Dramé, Emmanuel Hanon, Geert Leroux-Roels
Primary Institution: Centre for Vaccinology, Ghent University and Hospital, Ghent, Belgium
Hypothesis
Can an adjuvanted clade 1 H5N1 vaccine induce broad cross-protective immunity against clade 2 H5N1 viruses?
Conclusion
The adjuvanted H5N1 vaccine promotes broad and persistent cross-clade immunity, which is essential for pre-pandemic vaccination strategies.
Supporting Evidence
- The adjuvanted vaccine induced four-fold neutralising seroconversion rates in 85% of subjects against one strain and 75% against another.
- At six months post-vaccination, 70% and 60% of subjects retained neutralising antibodies against two different strains.
- No immune response was observed in the non-adjuvanted group.
Takeaway
This study shows that a special flu vaccine can help protect against different types of the H5N1 virus, which is important in case of a pandemic.
Methodology
A randomized, observer-blind clinical trial was conducted with two doses of the vaccine administered 21 days apart to healthy volunteers aged 18-60.
Potential Biases
Potential bias due to funding from GlaxoSmithKline, which was involved in all stages of the study.
Limitations
The study focused on a specific age group and may not be generalizable to all populations.
Participant Demographics
Participants were healthy adults aged 18-60, predominantly white Caucasian, with a gender ratio of approximately 75% female.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website